North American study and meta-analysis evaluating performance of Bladder EpiCheck<sup>®</sup>, a FDA cleared test, in non-muscle invasive bladder cancer recurrence
The consistently strong performance of BE indicate that a positive test could improve timely disease recurrence detection and a negative test could rule-out HG disease. Furthermore, the low rate of false positive results, potentially minimizes unnecessary downstream procedures and patient anxiety.
Authors
- Jason Hafron (ORCID: https://orcid.org/0000-0003-0866-797X)
- Neil Fleshner (ORCID: https://orcid.org/0000-0001-7407-7463)
- Ryan K. Berglund
- Lawrence I. Karsh (ORCID: https://orcid.org/0000-0002-3095-8303)
- J. Alfred Witjes (ORCID: https://orcid.org/0000-0003-0059-3857)
- Yair Lotan (ORCID: https://orcid.org/0000-0001-5692-2723)
- Kelvin A. Moses (ORCID: https://orcid.org/0000-0003-3231-2941)
- Brant A. Inman (ORCID: https://orcid.org/0000-0002-6060-4485)
- Jonathan Lawrence Wright (ORCID: https://orcid.org/0000-0002-8447-8209)
- Daniel R. Saltzstein
- H. Barton Grossman
- Anup Shah
Institutions
- Western University (CA)
- Cleveland Clinic (US)
- University Health Network (CA)
- Radboud University Nijmegen (NL)
- University of Washington (US)
- Radboud University Medical Center (NL)
- The Urology Center of Colorado (US)
- Urology San Antonio (US)
- Michigan Institute of Urology (US)
- Chesapeake Urology Associates (US)
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Bladder Cancer
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1177/23523735241304348
- Citations
- 4
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.29